Pre-exposure prophylaxis

SpikImm, a Biotech Company Founded by Truffle Capital and Institut Pasteur, Announces That Its Monoclonal Antibody Neutralises All SARS-COV-2 Variants of Concern, Including Omicron (BA.1 and BA.2)

Retrieved on: 
Wednesday, April 13, 2022
Research, Infectious Diseases, Finance, Consulting, Clinical Trials, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Partnership, CEO, Immunodeficiency, Foundation, Developmental biology, Institut Pasteur Korea, Delta, Lymphatic system, Microbiology, Pre-exposure prophylaxis, Vichy, Biotechnology, Research, Genomics, Acceleration, MD, Medicine, Therapy, Education, Severe acute respiratory syndrome coronavirus 2, Patient, Biomedical Research, Nobel Prize, Financial technology, Infection, Vaccination, AIDS, Medtech, List of life sciences, Neurodegeneration, Innovation, Degenerative disease, Hugo, Chief executive officer, Louis Pasteur, Public health, EUA, Multimedia, HIV, Pasteur Institute, Science, Cancer, Digital technology, Vaccine, Pharmaceutical industry, Neutralizing antibody, COVID19, Omicron

SpikImm expects to initiate clinical trials mid-2022 and then, to demonstrate the medical benefit in a phase 2 in immunocompromised patients.

Key Points: 
  • SpikImm expects to initiate clinical trials mid-2022 and then, to demonstrate the medical benefit in a phase 2 in immunocompromised patients.
  • SPK001 was selected among hundreds of screened anti-SARS-CoV-2 monoclonals, and cross-neutralizes all SARS-CoV-2 variants of concern including Delta, Omicron BA.1 and BA.2.
  • SpikImm was founded by Truffle Capital and Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID19 infection.
  • In 2019, Truffle Capital has announced the raising of nearly 400 million in new institutional funds, including 250 million in BioMedTech.

UT Southwestern's Dr. John Sweetenham Elected Board Chair for National Comprehensive Cancer Network

Retrieved on: 
Tuesday, April 5, 2022
People, FACP, Leukemia, Fox Chase Cancer Center, Haematopoietic system, Board, Caregiver, FRCP, Vaccination, Research, History of Cleveland Clinic, Associate, Patient, National Comprehensive Cancer Network, Cancer, Decision-making, CEO, NCCN, University of Texas Southwestern Medical Center, Health, Twitter, COVID-19, MBA, Lymphoma, Policy, Pre-exposure prophylaxis, Harold, Education, Medical device, Management, Pharmaceutical industry, Medicine, MD, Director

PLYMOUTH MEETING, Pa., April 5, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) today announced the election of John W. Sweetenham, MD, FRCP, FACP, FASCO, to the role of Chair of the Board of Directors and Matt Kalaycio, MD, FACP, as Vice-Chair.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 5, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN) today announced the election of John W. Sweetenham, MD, FRCP, FACP, FASCO, to the role of Chair of the Board of Directors and Matt Kalaycio, MD, FACP, as Vice-Chair.
  • We are honored to have them overseeing our board of directors, which includes members from 32 leading academic cancer centers across the United States."
  • Dr. Sweetenham is Professor of Medicine and Associate Director for Clinical Affairs at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern in Dallas, Texas.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authoriza

Retrieved on: 
Wednesday, March 30, 2022
Post-exposure prophylaxis, Hospital, Organ transplantation, Therapy, Virus, Face, Risk, Vaccination, Investment, Feinberg School of Medicine, Death, Infection, EUA, Incidence, Severe acute respiratory syndrome coronavirus 2, Food, PEP, Safety, Emergency Use Authorization, Nasdaq, COVID-19, MBA, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Pre-exposure prophylaxis, FDA, Division, Patient, Disease, Antibody, Pharmaceutical industry, Medicine, Delta, Omicron, Adagio

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19. EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID-19.

Key Points: 
  • Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo.
  • In the STAMP trial, adintrevimab showed prevention of hospitalization and death in the face of the highest-risk variant (Delta) to-date.
  • There were five (0.7%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group.
  • Words such as anticipates, believes, could, expects, intends, potential, projects, and future or similar expressions are intended to identify forward-looking statements.

Avita Celebrates Onsite Pharmacy Partnership with Crew Health in Orlando

Retrieved on: 
Monday, March 21, 2022
LGBTQ+, AIDS, Health, Consumer, Other Health, Pharmaceutical, Pharmacy, Population, Federally Qualified Health Center, Crew, AIDS service organization, Program, Health, Prescription, Pharmacist, STI, Travel, Pre-exposure prophylaxis, Solution, HIV, Patient, Partnership, Hospital, Health insurance, Avita

Avita , a leading national pharmacy services organization, partnered with Crew Health to open an onsite pharmacy at Crew Healths clinic in Orlando.

Key Points: 
  • Avita , a leading national pharmacy services organization, partnered with Crew Health to open an onsite pharmacy at Crew Healths clinic in Orlando.
  • The new Avita onsite pharmacy enables Crew Healths more than 5,000 patients to receive vital pharmacy services without leaving the building.
  • Were thrilled to partner with Crew Health to offer patients in the Orlando community a convenient, expert, and affirming option for their pharmacy care.
  • As a full-service pharmacy, Avita has proven experience in 340B program administration and onsite pharmacy management.

West Virginia Health Right Opens CommUNITY Wellness Center

Retrieved on: 
Thursday, March 17, 2022
AIDS, Professional Services, Managed Care, Other Health, Health, General Health, Mental Health, Infectious Diseases, Fitness & Nutrition, Insurance, Dental, Health equity, Central Avenue, Organization, Virginia Health Quality Center, Gaps, Corners, Transport, Multimedia, Parent, Friends, Homelessness, Medicaid, Health, Workforce, UniCare, Learning, Twitter, CHIP, Health education, Â, Food, Pre-exposure prophylaxis, HIV, Education, Hospital, Pharmaceutical industry, West Virginia Health Right, UniCare Health Plan of West Virginia, Inc., WEST VIRGINIA HEALTH RIGHT, UNICARE HEALTH PLAN OF WEST VIRGINIA, INC.

West Virginia Health Right today opened its CommUNITY Wellness Center at 515 Central Avenue on Charlestons West Side.

Key Points: 
  • West Virginia Health Right today opened its CommUNITY Wellness Center at 515 Central Avenue on Charlestons West Side.
  • Thanks to funding from a $1 million investment from UniCare Health Plan of West Virginia (UniCare) to West Virginia Health Right, the new center features four behavioral health offices, health education and community training space, childcare so parents easily can attend health appointments, a teaching kitchen, and an onsite gym.
  • West Virginia Health Right is thrilled to partner with UniCare Health Plan on these new initiatives, Angie Settle, West Virginia Health Rights chief executive officer, said.
  • About UniCare Health Plan of West Virginia, Inc.:
    UniCare Health Plan of West Virginia, Inc., serves more than 195,000 Medicaid and CHIP beneficiaries living in West Virginia.

Black Women's Learning Institute Releases Data from National Survey About Black Women's Primary Health Concerns

Retrieved on: 
Thursday, March 10, 2022
Awareness, HIV, Children's Learning Institute, America's Health Rankings, Every, Profile, Research, Public health, Partnership, Bias, HIV/AIDS, Human, Quality of life, Data management, Depression, Health, National Women's Health Network, Risk, Woman, EEE, City, Science, Health equity, Consultant, Mental health, Breast cancer, Treatment, Technology, Data science, Population, COVID-19, Pre-exposure prophylaxis, Institute of Museum and Library Services, Birth control, Pharmaceutical industry, Medicine, Black

According to America's Health Rankings (2018), these two cities represent a population of Black women known to experience higher rates of many serious health issues compared to Black women in other parts of the country.

Key Points: 
  • According to America's Health Rankings (2018), these two cities represent a population of Black women known to experience higher rates of many serious health issues compared to Black women in other parts of the country.
  • While HIV remains a major public health issue that disproportionately affects Black women, the survey revealed the top three health concerns were high blood pressure, depression, and breast cancer.
  • Only 4% of Black women respondents said that HIV/AIDS was a top health concern.
  • The conditions and circumstances in which people are born and live, and the social determinants of health, shape Black women's health outcomes.

Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues

Retrieved on: 
Tuesday, March 1, 2022
Research, Infectious Diseases, FDA, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, CD4, Risk, CRL, U.S. Securities and Exchange Commission, CAPELLA, Population, Lenacapavir, File, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Twitter, New Drug Application, Gilead Sciences, Subtypes of HIV, Plasma protein binding, Education, Diarrhea, Annual report, COVID-19, HIV, Pre-exposure prophylaxis, Nausea, Medicine, MDR, Private Securities Litigation Reform Act, Safety, CMC, Documentation, Review, Nasdaq, Food, AIDS, FDA, HIV-1, Cancer, Conference, Science, NDA, HTE, MD, Subclinical infection, Research, Solution, Doctor of Philosophy, Pharmaceutical industry

In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the proposed container vial as the reason for their action.

Key Points: 
  • In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the proposed container vial as the reason for their action.
  • Gilead intends to provide FDA with a comprehensive plan and corresponding data to use a different vial type.
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. All other trademarks are the property of their respective owners.
  • For more information about Gilead, please visit the companys website at www.gilead.com , follow Gilead on Twitter ( @Gilead Sciences ) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Human Immunodeficiency Virus (HIV) Epidemiology Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 15, 2022
Infectious Diseases, AIDS, Health, ART, HIV, Sex, Incidence, Prevalence, HCV, Epidemiology, Risk, Coinfection, Hepatitis B virus, Pre-exposure prophylaxis, HBV, Vaccine, Dietary supplement

The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Immunodeficiency Virus (HIV) - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The Human Immunodeficiency Virus (HIV) Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of HIV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • Diagnosed prevalent cases are further segmented by coinfection with hepatitis B virus (HBV), coinfection with hepatitis C virus (HCV), and cases on antiretroviral therapy (ART).
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in HIV.

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

Retrieved on: 
Monday, February 7, 2022
Policy, Pain, Pre-exposure prophylaxis, CDC, Cancer, Decision-making, Caregiver, FABS, Hospital, RNA transfection, Health, Myalgia, Fever, Fox Chase Cancer Center, Chills, Temple University, Department, Research, NCCN, Headache, National Comprehensive Cancer Network, Vaccination, Report, Public policy, Strathcona County, Education, Infection, MD, Radiation therapy, Harborside, Twitter, Incidence, Bioethics, Risk, Oncology, Patient, Review, Effectiveness, COVID-19, Journal of the National Comprehensive Cancer Network, Nausea, Pfizer, University of Wisconsin Carbone Cancer Center, Arthralgia, University, Immunotherapy, Death, Physician, Vaccine, Fatigue, Pharmaceutical industry, Medicine

PLYMOUTH MEETING, Pa., Feb. 7, 2022 /PRNewswire/ -- New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from Fox Chase Cancer Center tracked short-term side-effects from more than 1,753 recipients of the Pfizer BNT162b2 vaccine, and found no additional reactions for patients undergoing active cancer treatment (surgery, chemotherapy, immunotherapy, or radiation therapy) or who had completed treatment.

Key Points: 
  • "We now have the data and the clinical experience from thousands and thousands and thousands of cancer patients who have been vaccinated.
  • We know that the mRNA vaccines are safe and are absolutely the most effective way to prevent hospitalization and death from COVID-19."
  • This study demonstrates that cancer patients experience no greater rate of complications and should help to counteract misinformation about COVID-19 vaccinations.
  • More than 25,000 oncologists and other cancer care professionals across the United States readJNCCNJournal of the National Comprehensive Cancer Network.

mRNA COVID-19 Vaccines are Safe for People with Cancer According to New Study in JNCCN

Retrieved on: 
Monday, February 7, 2022
Policy, Pain, Pre-exposure prophylaxis, CDC, Cancer, Decision-making, Caregiver, FABS, Hospital, RNA transfection, Health, Myalgia, Fever, Fox Chase Cancer Center, Chills, Temple University, Department, Research, NCCN, Headache, National Comprehensive Cancer Network, Vaccination, Report, Public policy, Strathcona County, Education, Infection, MD, Radiation therapy, Harborside, Twitter, Incidence, Bioethics, Risk, Oncology, Patient, Review, Effectiveness, COVID-19, Journal of the National Comprehensive Cancer Network, Nausea, Pfizer, University of Wisconsin Carbone Cancer Center, Arthralgia, University, Immunotherapy, Death, Physician, Vaccine, Fatigue, Pharmaceutical industry, Medicine

PLYMOUTH MEETING, Pa., Feb. 7, 2022 /PRNewswire/ -- New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from Fox Chase Cancer Center tracked short-term side-effects from more than 1,753 recipients of the Pfizer BNT162b2 vaccine, and found no additional reactions for patients undergoing active cancer treatment (surgery, chemotherapy, immunotherapy, or radiation therapy) or who had completed treatment.

Key Points: 
  • "We now have the data and the clinical experience from thousands and thousands and thousands of cancer patients who have been vaccinated.
  • We know that the mRNA vaccines are safe and are absolutely the most effective way to prevent hospitalization and death from COVID-19."
  • This study demonstrates that cancer patients experience no greater rate of complications and should help to counteract misinformation about COVID-19 vaccinations.
  • More than 25,000 oncologists and other cancer care professionals across the United States readJNCCNJournal of the National Comprehensive Cancer Network.